All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RLS-0071
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RLS-0071
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
RLS-0071 is a dual targeting anti-inflammatory peptide that inhibits complement and inflammatory processes such as neutrophil activation and NETosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Umbilical cord derived mesenchymal stem cell
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: JadiCells
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
Company announced today filing of an IND application seeking permission from the Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial assessing safety and signals of efficacy for treatment of Chronic Traumatic Encephalopathy (CTE) patients with JadiCells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Xeno-Skin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Xeno-Skin
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
XenoTherapeutics has completed the first of two patient cohorts in the company’s Phase I trial of Xeno-Skin™, first-in-human, live-cell xenotransplant to treat severe and extensive burn wounds. As a result, the U.S. FDA has agreed to permit accelerated patient enrollment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NMT-cP12
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NMT-cP12
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
The Phase 1 clinical trial included five escalating dose cohorts of eight healthy volunteers each, that either received one intravenous dose of NMT-cP12 or a control (normal saline).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TRV027
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TRV027
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Imperial College London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Iron Sucrose,Stannous protoporphyrin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
Based on the results to be presented at ERA-EDTA, the company is currently planning a Phase 2 study to investigate whether RBT-1 upregulates the expression of these biomarkers of cytoprotection in patients scheduled to undergo cardiac surgery.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
